Immune Thrombocytopenia Epidemiology Study

Immune Thrombocytopenia (ITP) Epidemiology Study Objective:

To determine the prevalence and incidence of Immune Thrombocytopenia (ITP) among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Immune Thrombocytopenia (ITP) within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Immune Thrombocytopenia (ITP) Study USP:

• This epidemiological study on Immune Thrombocytopenia (ITP) stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.


• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Immune Thrombocytopenia (ITP) related health problems.


• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Immune Thrombocytopenia (ITP) but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Immune Thrombocytopenia (ITP) cases.

Immune Thrombocytopenia (ITP) related Study Overview:

The study defines Immune Thrombocytopenia (ITP) as an advanced form of disease. The significance of studying Immune Thrombocytopenia (ITP) epidemiology is due to its increasing prevalence in different age populations.

Immune Thrombocytopenia (ITP) Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Immune Thrombocytopenia (ITP) cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Immune Thrombocytopenia (ITP) Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Immune Thrombocytopenia (ITP) and potential risk factors (e.g., age, smoking, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.                                                                        

Immune Thrombocytopenia (ITP) study summary:

Immune Thrombocytopenia (ITP) study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Immune Thrombocytopenia (ITP) worldwide.

Immune Thrombocytopenia (ITP) overview:

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by low platelet count (thrombocytopenia) due to the immune system mistakenly attacking and destroying body’s own platelets.

Immune thrombocytopenia (ITP) is classified based on its duration: it is termed acute if it lasts less than 3 months, persistent if it lasts between 3 to 12 months, and chronic if it lasts more than 12 months.

The annual incidence of immune thrombocytopenia (ITP) varies across different regions, incidence of pediatric ITP is estimated to be between 1 and 6.4 cases per 100,000 people. In the United States, it is estimated at around 3.3 per 100,000 people. In Europe, the incidence among adults’ ranges from 1 to 4 per 100,000 people. Specifically, in Northern Europe, it is approximately 2.68 per 100,000 people, in Denmark, it is about 2.25 per 100,000 people. In France, the incidence is estimated at 2.9 per 100,000 people. In the United Kingdom, the incidence is around 1.6 per 100,000 people.

Therapeutics available in the market for the treatment of ITP include Corticosteroids, Intravenous Immunoglobulin, Thrombopoietin Receptor Agonists, Immunosuppressive Therapy. Key market players manufacturing therapeutics for the treatment of Immune Thrombocytopenia (ITP) include Zymeworks, Fujifilm Holdings, AbbVie, Teva Pharmaceutical Industries, Sobi, Amgen, Grifols, Roche, Kedrion Biopharma, Daiichi Sankyo, Pfizer, Novartis, Servier, Bristol Myers Squibb.

March 2024, Argenx has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART (efgartigimod alfa) for intravenous use in adults with primary immune thrombocytopenia (ITP). This approval marks the first global approval for VYVGART in ITP. The decision is based on results from the global Phase 3 ADVANCE-IV trial, which demonstrated that VYVGART significantly improved platelet counts in chronic ITP patients compared to placebo. The treatment showed a rapid onset of effect and a 51% response rate on the International Working Group (IWG) score. VYVGART was well-tolerated, with a safety profile consistent with previous clinical trials.

Immune Thrombocytopenia (ITP) Demographic and Environmental Risk Factors:

Age and Sex: Immune thrombocytopenia (ITP) has varying incidence rates across different age groups and sexes. In adults, the annual incidence is estimated to be between 1 to 6 cases per 100,000 people. Pediatric ITP can present at any age, with peak incidences occurring at ages 2 to 5 and during adolescence. The condition is more common among male children from infancy to childhood, whereas in adolescents and young adults (18 to 45 years), it is more prevalent among females. This predominance among women in these age groups is due to estrogen's effects, which can promote autoimmunity. The incidence of ITP in children ranges from 0.46 to 12.5 cases per 100,000 person-years, while in adults, it is estimated to be between 1.6 to 3.9 cases per 100,000 person-years.

Ethnicity: According to one of the study published in the American Society of Hematology, Black children had a significantly lower prevalence of ITP compared to White children. At the Children's Hospital of Philadelphia (CHOP), 7% of the 311 patients included in the study were Black, 76% were White, and 17% were classified as Other (including Asian, Middle Eastern, Mixed Race, and Native American/Pacific Islander). These proportions differ from the general CHOP patient population (22% Black, 55.5% White, and 22.5% Other) and the Philadelphia metro population (42.5% Black, 41.5% White, and 16% Other). The frequency of chronic ITP was also higher among Black patients in the CHOP cohort.

Risk Factors causing Immune Thrombocytopenia (ITP): The risk of developing immune thrombocytopenia (ITP) increases based on demographic factors such as age and sex. Exposure to bacterial infections (e.g., Helicobacter pylori) and viral infections (e.g., hepatitis C, HIV, Epstein-Barr virus, cytomegalovirus, COVID-19) can trigger autoimmune responses leading to ITP. Polymorphisms in genes related to immune system functioning, such as those encoding B-cell activating factor, mannose-binding lectin, glycoprotein, and various cytokines and chemokines (e.g., IL-1, IL-2, IL-4, IL-6, IL-10, IL-17, TNFα, TGF-β, IFN-γ), are associated with a higher likelihood of developing ITP. Certain drugs, including heparin, chemotherapeutic agents, antirheumatic agents, antimicrobial agents, platelet inhibitors, cinchona alkaloids, and histamine-receptor antagonists, can also increase the risk of developing ITP.

Immune Thrombocytopenia (ITP) Market Scope:

Drivers: Increasing Incidence of Immune Thrombocytopenia

The increasing prevalence of immune thrombocytopenia (ITP) is a significant driver for the Immune Thrombocytopenia (ITP) Market Industry. As awareness about the condition grows and advancements in diagnostic procedures enhance early detection, more individuals are seeking medical attention for their symptoms. This rise in diagnosis translates into a higher demand for therapeutic options. The increase in lifestyle factors that contribute to autoimmune diseases, alongside environmental triggers, is thought to elevate the incidence of ITP. Moreover, the aging population is more susceptible to immune-related disorders, consequently contributing to a greater number of diagnosed cases. This ongoing rise in the patient population fosters the need for targeted treatments and therapies, pushing pharmaceutical companies to innovate and invest in new solutions tailored specifically for ITP patients. Such developments not only enhance patient outcomes but simultaneously bolster market growth, as healthcare providers and stakeholders recognize the potential seen in addressing this condition. Enhanced patient awareness campaigns are also bringing to light the importance of recognizing ITP, which is further likely to create additional opportunities within the Immune Thrombocytopenia (ITP) Market Industry.

Restraints: High treatment cost, limited awareness and underdiagnosis, adverse effects of the available therapies, strict regulatory framework delaying the product launch are some of the hurdles which can contribute to hampering the growth of the market manufacturing the therapeutics for the treatment of the ITP.